• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.

作者信息

Jovani Vega, Calabuig Irene, Peral-Garrido Maria Luisa, Tovar-Sugrañes Ernesto, López-González María-Del-Carmen, Bernabeu Pilar, Martínez Agustín, Esteve-Vives Joaquim, León-Ramírez Jose-Manuel, Moreno-Perez Oscar, Boix Vicente, Gil Joan, Merino Esperanza, Vela Paloma, Andrés Mariano

机构信息

Reumatología, Hospital General Universitario de Alicante, Alicante, Spain

Reumatología, Hospital General Universitario de Alicante, Alicante, Spain.

出版信息

Ann Rheum Dis. 2022 Jul;81(7):e131. doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25.

DOI:10.1136/annrheumdis-2020-218152
PMID:32586922
Abstract
摘要

相似文献

1
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.西班牙一个由1037名接受生物制剂和JAK抑制剂治疗的风湿病患者组成的队列中重症新型冠状病毒肺炎的发病率。
Ann Rheum Dis. 2022 Jul;81(7):e131. doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25.
2
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani .对乔瓦尼所著《西班牙1037例接受生物制剂和JAK抑制剂治疗的风湿病患者中重症COVID-19的发病率》的回应
Ann Rheum Dis. 2022 Jul;81(7):e132. doi: 10.1136/annrheumdis-2020-218179. Epub 2020 Jun 25.
3
What is the true incidence of COVID-19 in patients with rheumatic diseases?风湿性疾病患者中新型冠状病毒肺炎的真实发病率是多少？
Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.
4
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
5
The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?JAK抑制剂：它们会给风湿性疾病的治疗带来范式转变吗？
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i1-i3. doi: 10.1093/rheumatology/key280.
6
Peri-Arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease A Survey of Practice Trends Among Rheumatologists and Sports Medicine Orthopedic Surgeons.关节镜周围治疗风湿性疾病患者免疫抑制药物：风湿科医生和运动医学骨科医生实践趋势调查。
Bull Hosp Jt Dis (2013). 2024 Sep;82(3):186-193.
7
JAK inhibitors in rheumatology.风湿病学中的JAK抑制剂
Immunol Med. 2023 Sep;46(3):143-152. doi: 10.1080/25785826.2023.2172808. Epub 2023 Feb 6.
8
[Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].[类风湿关节炎的药物治疗：生物制剂和新型合成改善病情抗风湿药目前处于什么地位？]
Inn Med (Heidelb). 2023 Oct;64(10):1005-1012. doi: 10.1007/s00108-023-01554-6. Epub 2023 Jul 26.
9
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.在对肿瘤坏死因子抑制剂反应不足的活动性类风湿关节炎患者中，非肿瘤坏死因子生物制剂和 Janus 激酶抑制剂的比较有效性和安全性：一项随机对照试验的贝叶斯网络荟萃分析
J Clin Pharm Ther. 2021 Aug;46(4):984-992. doi: 10.1111/jcpt.13380. Epub 2021 Feb 18.
10
[Biologics and further new drugs for rheumatic diseases since 2000].[2000年以来用于风湿性疾病的生物制剂及其他新药]
Orthopade. 2018 Nov;47(11):906-911. doi: 10.1007/s00132-018-3650-4.

引用本文的文献

1
COVID-19 Infection and Clinical Outcomes in Hospitalized Patients With Rheumatoid Arthritis: Insights From the National Inpatient Sample.类风湿关节炎住院患者的新冠病毒感染及临床结局：来自全国住院患者样本的见解
J Community Hosp Intern Med Perspect. 2024 Jan 12;14(1):5-12. doi: 10.55729/2000-9666.1288. eCollection 2024.
2
COVID-19 and Pediatric Rheumatology: A Comprehensive Study from a Leading Tertiary Center in Saudi Arabia.COVID-19 与儿科风湿病学：沙特阿拉伯一家领先的三级中心的综合研究。
J Epidemiol Glob Health. 2023 Dec;13(4):676-684. doi: 10.1007/s44197-023-00142-z. Epub 2023 Aug 18.
3
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.
专家共识：影响 COVID-19 预后不良的主要危险因素及其对靶向 SARS-CoV-2 措施的影响。
Viruses. 2023 Jun 27;15(7):1449. doi: 10.3390/v15071449.
4
A prospective analysis of the long-term impact of the COVID-19 pandemic on well-being and health care among children with a chronic condition and their families: a study protocol of the KICK-COVID study.一项关于 COVID-19 大流行对慢性病患儿及其家庭的幸福感和医疗保健的长期影响的前瞻性分析：KICK-COVID 研究的研究方案。
BMC Pediatr. 2023 Mar 22;23(1):130. doi: 10.1186/s12887-023-03912-7.
5
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.2019冠状病毒病与免疫介导的炎症性疾病：疾病及治疗对2019冠状病毒病结局和疫苗反应的影响
Lancet Rheumatol. 2021 Oct;3(10):e724-e736. doi: 10.1016/S2665-9913(21)00247-2. Epub 2021 Aug 27.
6
Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity.性别的药理学和 COVID-19：迈向适当性和健康公平的下一步。
Pharmacol Res. 2021 Nov;173:105848. doi: 10.1016/j.phrs.2021.105848. Epub 2021 Aug 26.
7
Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.儿童和青少年风湿性肌肉骨骼疾病患者感染 SARS-CoV-2 的临床表现和结局：来自德国国家儿科风湿病数据库的数据。
RMD Open. 2021 Jul;7(2). doi: 10.1136/rmdopen-2021-001687.
8
New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.银屑病研究的新前沿，第二部分：合并症和靶向治疗。
J Invest Dermatol. 2021 Oct;141(10):2328-2337. doi: 10.1016/j.jid.2021.02.743. Epub 2021 Apr 19.
9
Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel.以色列一家三级转诊诊所的风湿科患者人群中 COVID-19 的流行情况和对 SARS-CoV-2 的血清流行率。
Intern Med J. 2021 May;51(5):682-690. doi: 10.1111/imj.15202. Epub 2021 May 12.
10
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.COVID-19 疫苗接种在自身免疫性炎症性风湿病患者中的应用：韩国风湿病学会的临床指南。
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.